Hikma intros ephedrine sulfate

Hikma is offering ephedrine sulfate injection in a dosage strength of 50mg/mL.

The product is an alpha- and beta- adrenergic agonist and a norepinephrine releasing agent indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Ephedrine sulfate injection had a market value of approximately $64 million in the 12 months ended November 2020, according to IQVIA.